Monoclonal antibody
Type Whole antibody
Source Humanized
Target CD19
Clinical data
ATC code none
CAS Number 1299440-37-1
ChemSpider none
Chemical and physical data
Formula C6504H10080N1732O2044S44
Molar mass 147 kDa

Inebilizumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer, systemic sclerosis and multiple sclerosis.[1][2]

This drug was developed by MedImmune, LLC.


  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Inebilizumab, American Medical Association.
  2. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.